Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2021-07-16 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司关于召开2021年第一次临时股东大会的提示性公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2021 first extraordinary general meeting of shareholders (临时股东大会) for 金宇生物技术股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items to be discussed and voted on, instructions for shareholders on registration and voting, and an authorization proxy form. The content focuses on procedural and logistical details for the shareholders' meeting and the specific proposals to be voted on, including non-public issuance of A shares and amendments to company bylaws. There is no financial data, earnings information, or management discussion of results. The document is not a report itself but an announcement and notice about the meeting and voting process. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation materials or proxy statement itself, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it includes detailed voting agenda and instructions for shareholders to vote, which is typical for voting rights announcements. The document length is about 4832 characters, which is consistent with a detailed announcement rather than a full report or proxy statement.
2021-07-16 Chinese
金宇生物技术股份有限公司2021年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2021 First Extraordinary General Meeting (EGM)" of 金宇生物技术股份有限公司. It contains detailed agenda items and proposals for shareholder approval, including non-public issuance of A shares, related-party transactions, amendments to the company charter, authorization for the board to handle issuance matters, and reports on prior fundraising usage. The content is typical of meeting materials prepared for a shareholders' meeting, providing information and proposals for voting. It is not a report itself (like an annual or interim report), nor is it a voting results announcement or a proxy statement. It is also not a presentation or transcript. The document is comprehensive and lengthy (15,000 characters), consistent with detailed meeting materials. Therefore, the document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting.
2021-07-16 Chinese
金宇生物技术股份有限公司关于子公司取得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary obtaining a new veterinary drug registration certificate. It details the product, its development, regulatory approval, and expected impact on the company. The document is short (1486 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an official announcement about a regulatory approval related to product registration, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-07-15 Chinese
金宇生物技术股份有限公司详式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is a detailed report titled "详式权益变动报告书" (Detailed Equity Change Report) for JinYu Biotechnology Co., Ltd. It is filed with the Shanghai Stock Exchange and involves a significant equity change due to a non-public stock issuance subscription by a controlling shareholder. The content includes detailed information about the equity holders, shareholding percentages before and after the transaction, the purpose of the equity change, the subscription agreement, funding sources, and future plans. This type of document corresponds to a Major Shareholding Notification, as it reports a change in significant share ownership levels, including becoming the controlling shareholder. It is not an announcement of a report publication, nor a general regulatory filing, nor a financial report. Therefore, the correct classification is Major Shareholding Notification (MRQ). The document length (15,000 characters) and detailed content support a high confidence level.
2021-07-09 Chinese
金宇生物技术股份有限公司前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use of previously raised funds by the company, including specifics on the amount raised, storage, usage, investment projects, and compliance with regulatory requirements. It references approvals by the China Securities Regulatory Commission and includes audited verification reports. The content focuses on the management and use of funds raised through a non-public stock issuance, with detailed financial figures and project progress. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is over 5,000 characters and contains substantive financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-07-07 Chinese
金宇生物技术股份有限公司关于召开2021年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2021 first extraordinary general meeting (临时股东大会) of the company 金宇生物技术股份有限公司. It includes information about the meeting date, voting methods (including online voting), agenda items for shareholder approval, registration procedures, and proxy authorization forms. The content focuses on the announcement and procedural details for the shareholders' meeting rather than the meeting materials or results. There is no indication that this is a report of voting results or a proxy solicitation document. It is not an annual or interim report, earnings release, or any financial statement. The document is a formal announcement notifying shareholders about the upcoming extraordinary general meeting and how to participate. Therefore, it fits best into the category of Declaration of Voting Results & Voting Rights Announcements (DVA) if it contained voting results, but since it is a notice of the meeting itself, it is more aligned with Proxy Solicitation & Information Statement (PSI) or AGM Information (AGM-R). However, since this is an extraordinary shareholders meeting notice (临时股东大会) and includes detailed agenda and proxy forms, it is best classified as Proxy Solicitation & Information Statement (PSI). The document length is 4690 characters, which is sufficient for a full notice rather than a brief announcement. Hence, the classification is PSI with high confidence.
2021-07-07 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.